Skip to main content

Table 3 Stepwise regression analysis of risk factors for increased areas of retinal pigment epithelial atrophy during three-year follow-up period of ranibizumab monotherapy

From: Retinal pigment epithelial atrophy over polypoidal choroidal vasculopathy lesions during ranibizumab monotherapy

Characteristic

Standardized regression coefficient

95 % confidence interval

P value

Baseline PCV area

0.32

0.23 to 0.40

0.001

Baseline RPE

   

 atrophic area

0.379

0.32 to 0.45

0.001

  1. Larger PCV lesions and larger RPE atrophic areas at baseline are associated significantly (adjusted R2 = 0.43, P = 0.001) with increased RPE atrophic areas during ranibizumab therapy
  2. PCV polypoidal choroidal vasculopathy, RPE retinal pigment epithelium